| Literature DB >> 33817388 |
Ayoub Khaldan1, Soukaina Bouamrane1, Fatima En-Nahli1, Reda El-Mernissi1, Khalil El Khatabi1, Rachid Hmamouchi1, Hamid Maghat1, Mohammed Aziz Ajana1, Abdelouahid Sbai1, Mohammed Bouachrine1,2, Tahar Lakhlifi1.
Abstract
Coronavirus (COVID-19), an enveloped RNA virus, primarily affects human beings. It has been deemed by the World Health Organization (WHO) as a pandemic. For this reason, COVID-19 has become one of the most lethal viruses which the modern world has ever witnessed although some established pharmaceutical companies allege that they have come up with a remedy for COVID-19. To that end, a set of carboxamides sulfonamide derivatives has been under study using 3D-QSAR approach. CoMFA and CoMSIA are one of the most cardinal techniques used in molecular modeling to mold a worthwhile 3D-QSAR model. The expected predictability has been achieved using the CoMFA model (Q2 = 0.579; R2 = 0.989; R2test = 0.791) and the CoMSIA model (Q2 = 0.542; R2 = 0.975; R2test = 0.964). In a similar vein, the contour maps extracted from both CoMFA and CoMSIA models provide much useful information to determine the structural requirements impacting the activity; subsequently, these contour maps pave the way for proposing 8 compounds with important predicted activities. The molecular surflex-docking simulation has been adopted to scrutinize the interactions existing between potentially and used antimalarial molecule on a large scale, called Chloroquine (CQ) and the proposed carboxamides sulfonamide analogs with COVID-19 main protease (PDB: 6LU7). The outcomes of the molecular docking point out that the new molecule P1 has high stability in the active site of COVID-19 and an efficient binding affinity (total scoring) in relation with the Chloroquine. Last of all, the newly designed carboxamides sulfonamide molecules have been evaluated for their oral bioavailability and toxicity, the results point out that these scaffolds have cardinal ADMET properties and can be granted as reliable inhibitors against COVID-19.Entities:
Keywords: 3D-QSAR; Carboxamides sulfonamide; Drug discovery; In silico ADMET; Molecular docking; SARS-CoV-2
Year: 2021 PMID: 33817388 PMCID: PMC7997311 DOI: 10.1016/j.heliyon.2021.e06603
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Figure 1General structure of carboxamides sulfonamide derivatives.
Experimental pMIC values of 18 carboxamides sulfonamide analogs and their chemical structures.
| N° | Structure | MIC (μM) | pMIC | |
|---|---|---|---|---|
| R1 | R2 | |||
| CH3 | H | 0.72 | 6.143 | |
| CH3 | 0.78 | 6.108 | ||
| CH3 | 0.03 | 7.523 | ||
| CH3 | 0.17 | 6.770 | ||
| CH3 | 5.11 | 5.292 | ||
| CH3 | 2.82 | 5.550 | ||
| NO2 | H | 0.18 | 6.745 | |
| NO2 | 0.08 | 7.097 | ||
| NO2 | 0.02 | 7.699 | ||
| NO2 | 0.06 | 7.222 | ||
| NO2 | 0.20 | 6.699 | ||
| NO2 | 1.57 | 5.804 | ||
| H | H | 0.97 | 6.013 | |
| H | 0.90 | 6.046 | ||
| H | 0.05 | 7.301 | ||
| H | 0.26 | 6.585 | ||
| H | 1.25 | 5.903 | ||
| H | 1.70 | 5.770 | ||
Test set molecules.
Figure 2Alignment of 18 carboxamides sulfonamides derivatives using molecule 9 as a template.
PLS Statistic indicators of CoMFA and CoMSIA models.
| Model | Q2 | R2 | SEE | F | N | R2test | Fractions | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ster | Elec | Hyd | Acc | Don | |||||||
| CoMFA | 0.579 | 0.989 | 0.097 | 209.678 | 4 | 0.791 | 0.536 | 0.464 | - | - | - |
| CoMSIA | 0.542 | 0.975 | 0.148 | 88.931 | 4 | 0.964 | 0.115 | 0.321 | 0.277 | 0.128 | 0.159 |
Q2: Cross-validated correlation coefficient; R2: Non-cross-validated correlation coefficient; SEE: Standard error of the estimate.
N: Optimum number of components; F: F-test value; R2test: External validation correlation coefficient.
Figure 3Plots of experimental and predicted pMIC values for the 18 carboxamides sulfonamide used in CoMFA and CoMSIA models.
Experimental and predicted pMIC of 18 carboxamides sulfonamide derivatives and their residuals.
| No | pMIC | CoMFA | CoMSIA | ||
|---|---|---|---|---|---|
| Predicted | Residuals | Predicted | Residuals | ||
| 6.143 | 6.017 | 0.126 | 6.156 | -0.013 | |
| 6.108 | 6.074 | 0.034 | 6.220 | -0.112 | |
| 7.523 | 7.474 | 0.049 | 7.460 | 0.063 | |
| 6.770 | 6.829 | -0.059 | 6.879 | -0.109 | |
| 5.292 | 5.384 | -0.092 | 6.022 | -0.730 | |
| 5.550 | 5.338 | 0.212 | 5.753 | -0.203 | |
| 6.745 | 6.596 | 0.149 | 6.043 | 0.702 | |
| 7.097 | 7.253 | -0.156 | 7.175 | -0.078 | |
| 7.699 | 7.625 | 0.074 | 7.684 | 0.015 | |
| 7.222 | 7.102 | 0.120 | 6.541 | 0.681 | |
| 6.699 | 6.310 | 0.389 | 6.535 | 0.164 | |
| 5.804 | 6.054 | -0.250 | 5.860 | -0.056 | |
| 6.013 | 6.039 | -0.026 | 6.376 | -0.363 | |
| 6.046 | 6.178 | -0.132 | 5.803 | 0.243 | |
| 7.301 | 7.275 | 0.026 | 7.469 | -0.168 | |
| 6.585 | 6.664 | -0.079 | 6.584 | 0.001 | |
| 5.903 | 5.781 | 0.122 | 5.953 | -0.050 | |
| 5.770 | 5.700 | 0.070 | 5.758 | 0.012 | |
Test set molecules.
Figure 4a) Steric and b) Electrostatic contours maps of CoMFA model using compound 9 as a reference.
Figure 5a) Steric, b) Electrostatic, c) Hydrophobic, d) H-bond donor and e) H-bond acceptor contours maps of CoMSIA analysis using compound 9 as a reference.
Figure 6Summary of contour maps for antimalarial activity generated by CoMFA and CoMSIA models.
Q2 and R2 values after several Y-randomization tests.
| Iteration | CoMFA | CoMSIA | ||
|---|---|---|---|---|
| Q2 | R2 | Q2 | R2 | |
| 1 | -0.089 | 0.945 | -0.114 | 0.895 |
| 2 | 0.007 | 0.962 | 0.038 | 0.877 |
| 3 | 0.094 | 0.963 | 0.089 | 0.895 |
| 4 | -0.018 | 0.956 | -0.257 | 0.875 |
| 5 | 0.002 | 0.956 | -0.266 | 0.872 |
Chemical structures of newly designed compounds and their predicted pMIC based on CoMFA and CoMSIA models.
| N° | Structure | Predicted pMIC | ||
|---|---|---|---|---|
| R1 | R2 | CoMFA | CoMSIA | |
| CN | 7.856 | 8.382 | ||
| CN | 7.753 | 8.492 | ||
| NO | 7.673 | 8.571 | ||
| NO | 7.528 | 8.373 | ||
| NO | 7.530 | 8.361 | ||
| NO | 7.477 | 8.333 | ||
| CN | 7.661 | 8.033 | ||
| NO2 | 7.844 | 7.973 | ||
Figure 7The interaction modes of the more potent molecule (compound 9) and COVID-19 main protease.
Figure 8The blind docked conformations of Chloroquine in the active site of COVID-19 main protease.
Figure 9Docking interactions between the proposed compound P1 and COVID-19 main protease.
Figure 103D View of the binding conformation of the compound 9 at the active site of COVID-19 main protease (Hydrogen Bond (a) and hydrophobicity (b) interactions).
Docking interactions and total scoring of compound 9, Chloroquine and P1 with 6LU7 receptor.
| Compounds | Residues | Scoring |
|---|---|---|
| Compound | Asp 153, Ser 158, Gln 110, Asn 151, Val 104, Lys 102, Phe 294 | 4.11 |
| Chloroquine | Thr 111, Asp 153, Val 104, Ile 106 | 3.51 |
| Phe 294, Gln 110, Phe 8, Ile 106, Val 297, Ile 249, Asp 153 | 4.46 |
Figure 11Superimposing of default conformation (Yellow colored) on docked conformation (Green colored) of the co-crystallized ligand N3 validating docking simulation.
Figure 12The Blind Docked conformations of inhibitor N3 (co-crystallized ligand) and SARS-CoV-2 protein.
In silico ADMET prediction and synthetic accessibility values of the new 8 carboxamides sulfonamide derivatives.
| Models | Compounds | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| P1 | P2 | P3 | P4 | P5 | P6 | P7 | P8 | ||
| Water solubility | Numeric (Log mol/L) | -3.87 | -3.98 | -3.84 | -3.94 | -3.87 | -3.93 | -3.96 | -3.48 |
| Caco-2 permeability | Numeric (log Papp in 10−6 cm/s) | 0.90 | 0.83 | 0.84 | 0.77 | 0.74 | 0.83 | 0.89 | 0.08 |
| Intestinal absorption (human) | Numeric (% Absorbed) | 90.09 | 91.49 | 92.49 | 93.89 | 94.51 | 92.37 | 89.97 | 89.58 |
| P-glycoprotein substrate | Categorical (Yes/No) | No | No | No | No | No | No | No | No |
| P-glycoprotein inhibitor | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | |
| Blood-brain barrier (logBB) | Numeric (log BB) | -0.65 | -1.09 | -0.86 | -0.85 | -0.84 | -0.88 | -0.67 | -1.00 |
| CYP1A2 inhibitor | Categorical (Yes/No) | No | No | No | No | No | No | No | No |
| CYP2C9 inhibitor | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | |
| CYP2D6 inhibitor | No | No | No | No | No | No | No | No | |
| CYP2C19 inhibitor | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | |
| CYP3A4 inhibitor | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | |
| CYP2D6 substrate | No | No | No | No | No | No | No | No | |
| CYP3A4 substrate | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | |
| Total Clearance | Numeric (log ml/min/kg) | -0.09 | 0.01 | -0.18 | -0.07 | -0.01 | -0.01 | 0.07 | -0.003 |
| AMES toxicity | Categorical (Yes/No) | No | No | No | No | No | No | No | No |
| Synthetic accessibility | Numeric | 4.92 | 5.19 | 4.89 | 5.15 | 5.01 | 4.77 | 4.80 | 4.82 |